FDA Inspection Growth In China Stymied By Visa Issues
This article was originally published in PharmAsia News
The agency is waiting for approval to locate 10 new drug inspectors in China.
You may also be interested in...
Despite being one of the largest medical product markets in the world, China has seen few product recalls. The situation could be changing however as China FDA has requested drug and device manufacturers to quickly withdraw products that have deficiencies and potential safety risks.
User fees, not appropriations, will make up the bulk of FDA’s human drug spending if President Obama’s FY 2014 budget comes to pass, a trend fueled by new user fee programs and cuts to taxpayer funding.
U.S. FDA could help create several international coalitions to carry out its new globalization plan, which could allow for issue-specific groups focused on individual pharmaceutical sectors